STAT3/STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma.

Abstract excerpt

INTRODUCTION: Plasma cell myeloma is a heterogeneous hematologic malignancy characterized by clonal expansion of plasma cells. While RAS-MAPK pathway mutations are known high-risk features, the clinical relevance of STAT3/STAT5 mutations remains unclear. METHOD: We analyzed 16 myeloma patients with STAT3/STAT5 mutations identified by next-generation sequencing (9 STAT3, 5 STAT5A, 2 STAT5B) and compared them with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers, Tumor
• Share to DNA Mutational Analysis